Drug development in oncology commonly exploits the tools of molecular biology to gain
therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) …

The long-term efficacy of targeted therapeutics for cancer treatment can be significantly
limited by the type of therapy and development of drug resistance, inter alia. Experimental …

To understand the diversity of immune responses to SARS-CoV-2 and distinguish features
that predispose individuals to severe COVID-19, we developed a mechanistic, within-host …

Oncolytic viruses are of growing interest to cancer researchers and clinicians, due to their
selectivity for tumor cells over healthy cells and their immunostimulatory properties. The …

More and more evidences show that macrophages can induce both pro-tumor and anti-
tumor effects. The study on genetically engineered macrophages to kill tumor cells has …

The 2019 novel coronavirus, SARS-CoV-2, is a pathogen of critical significance to
international public health. Knowledge of the interplay between molecular-scale virus …

The development of new techniques for anti-cancer therapy has become a very active area
of research in recent years. One of the promising directions of anti-cancer therapy aims at …

Detailed, mechanistic models of immune cell behavior across multiple scales in the context
of cancer provide clinically relevant insights needed to understand existing …

Cancer is a common term for many diseases that can affect anybody. A worldwide leading
cause of death is cancer, according to the World Health Organization (WHO) report. In 2020 …

Simple Summary A combination of oncolytic viral therapy and immunotherapy provides an
alternative option to the standard of care for treating the lethal brain tumor glioblastoma …